login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PROPANC BIOPHARMA INC (PPCB) Stock News
USA
- NASDAQ:PPCB -
US74346N7012
-
Common Stock
1.52
USD
+0.04 (+2.7%)
Last: 10/24/2025, 8:00:01 PM
1.4807
USD
-0.04 (-2.59%)
After Hours:
10/24/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PPCB Latest News, Press Relases and Analysis
All
Press Releases
11 days ago - By: Propanc Biopharma, Inc.
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
11 days ago - By: Propanc Biopharma, Inc.
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
12 days ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
12 days ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
20 days ago - By: Propanc Biopharma, Inc.
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
20 days ago - By: Propanc Biopharma, Inc.
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
a month ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
a month ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
2 months ago - By: Stocktwits
Why Propanc stock Is Tumbling In Premarket Today
2 months ago - By: Benzinga
- Mentions:
MTNB
TPIC
RSKD
VTAK
...
US Stocks Mixed; Riskified Shares Dip After Q2 Results
2 months ago - By: Benzinga
- Mentions:
BRKR
SLRX
LUNG
HOTH
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
2 months ago - By: ACCESS Newswire
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Provides Shareholder Update
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Provides Shareholder Update
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
2 months ago - By: Propanc Biopharma, Inc.
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
a year ago - By: Propanc Biopharma, Inc.
- Mentions:
OTC
Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest
a year ago - By: Propanc Biopharma, Inc.
- Mentions:
OTC
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
a year ago - By: Propanc Biopharma, Inc.
- Mentions:
OTC
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
a year ago - By: Propanc Biopharma, Inc.
- Mentions:
OTC
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
2 years ago - By: Propanc Biopharma, Inc.
- Mentions:
OTC
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
Please enable JavaScript to continue using this application.